FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy

Teva Pharmaceutical Industries Ltd.

today announced that the U.S. Food and Drug Administration (FDA) has approved Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy. Quartette™ represents the next generation of extended regimen oral contraceptives to be approved by the FDA, and was designed to minimize breakthrough bleeding (BTB) between scheduled periods. The approval of Quartette™ demonstrates Teva's continued commitment to the development and production of an innovative range of pharmaceutical products that support the health of women around the world. “Breakthrough bleeding can be experienced with any birth control pill, especially during the first few months, and is one of the reasons a large